06127 JOINN
- 8.690
- +0.380+4.57%
JOINN News
Nomura Adjusts Joinn Laboratories' Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral
05:40 AM EDT, 04/30/2024 (MT Newswires) -- Nomura Adjusts Joinn Laboratories' Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral Price (RMB): ¥16.39, Change: ¥-1.82, Percent Change: -9.99%
Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell by more than 11%, and the impact of experimental impairment increased the company's year-on-year change from profit to loss in the first quarter
Zhaoyan Pharmaceutical (06127) fell by more than 11%. As of press release, it was down 11.12% to HK$8.79, with a turnover of HK$14.2872 million.
Zhaoyan Pharmaceutical (06127) lost 272 million yuan to mother in the first quarter
According to the Zhitong Finance App, Zhaoyan Pharmaceutical (06127) released its report for the first quarter of 2024. Operating revenue was 325 million yuan (RMB, same below), down 12.07% year on year; net loss attributable to shareholders of listed companies was 272 million yuan, profit of 188 million yuan for the same period last year; basic loss per share was 0.36 yuan.
昭衍新藥：2024年度第一季度報告
昭衍新藥：2023年度報告
Zhaoyan New Pharmaceutical (06127): Wuxi Jinyifu New Biomedical Venture Capital Partnership (Limited Partnership) adds limited partner Xiangtang Heyi
Zhaoyan New Pharmaceutical (06127) was announced. On February 5, 2024, the board of directors reviewed and approved the “About...
Joinn Laboratories(China)Co.Ltd's (SHSE:603127) Soft Earnings Don't Show The Whole Picture
The market for Joinn Laboratories(China)Co.,Ltd.'s (SHSE:603127) shares didn't move much after it posted weak earnings recently. We did some digging, and we believe the earnings are stronger than the
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 9%, leading the CRO concept pharmaceutical industry's transformation to innovative drugs and a gradual recovery in biomedical investment and financing
The Zhitong Finance App learned that CRO concept stocks rose collectively. As of press release, Tiger Pharmaceuticals (03347) rose 8.8% to HK$30.3; Zhaoyan Pharmaceutical (06127) rose 6.43% to HK$8.77; Pharmaceutical Biotech (02269) rose 6.59% to HK$14.24; Zhaoyan Pharmaceutical (06127) rose 6.43% to HK$8.77; Pharmaceuticals (02359) rose 3.56% to HK$36.4. Dongwu Securities pointed out that the global CRO market is expanding steadily. Among them, the growth rate of the Chinese CRO market is higher than that of the world, while the clinical CRO market
Changes in Hong Kong stocks | Kanglong Chemical (03759) falls by more than 8%, leading the decline in the CRO concept stock industry's growth rate is slowing, and macro risk factors have yet to be implemented
The Zhitong Finance App learned that CRO concept stocks had the highest decline. As of press release, Kanglong Chemical (03759) fell 8.35% to HK$8.78; Zhaoyan Pharmaceutical (06127) fell 6.59% to HK$8.64; Pharmaceutical Kangde (02359) fell 6.45% to HK$36.8; and Tiger Pharmaceuticals (03347) fell 6.29% to HK$27.55. According to the news, according to the Shanghai Securities Report, CXO's leading annual reports have been released one after another recently. Judging from financial data, the performance of Yao Ming Kangde and Kanglong Chemical has achieved varying degrees of growth; in addition, Tiger Pharma's various performance indicators
Zhaoyan New Pharmaceutical (603127.SH): Shares have not been repurchased
Gelonghui, April 2, 丨 Zhaoyan New Pharmaceutical (603127.SH) announced that as of March 31, 2024, the company had not repurchased the shares.
Joinn Laboratories' Profit Slumps 63% in 2023, Misses Estimates
Joinn Laboratories' (HKG:6127) net profit attributable to shareholders declined 63% to 397 million yuan in the year ended Dec. 31, 2023, from 1.1 billion yuan a year ago, according to a March 28 filin
Zhaoyan Pharmaceutical (06127) plans to distribute 2023 cash dividends of 0.16 yuan per share
Zhaoyan Pharmaceutical (06127) announced that it intends to distribute a 2023 cash dividend of RMB 0.16 per share (including...
JOINN: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Zhaoyan Pharmaceutical (603127.SH) released 2023 results, net profit of 397 million yuan, a year-on-year decrease of 63.04%
Zhaoyan New Pharmaceutical (603127.SH) released its 2023 annual report, achieving operating revenue of 2,376 billion yuan,...
Medication heats up strongly! Pharmaceutical stocks are rebounding, and the US “Biosafety Act” suddenly becomes a variable?
Also boosted by these factors!
Changes in Hong Kong stocks | CRO concept stocks generally fall in early trading, Kant expects this year's revenue growth to hit a ten-year low, Citi says the guidelines are disappointing
CRO concept stocks generally declined in early trading. As of press release, Pharmaceuticals (02359) fell 4.86% to HK$38.2; Tiger Pharmaceuticals (03347) fell 4.48% to HK$29.85; Zhaoyan Pharmaceutical (06127) fell 4.47% to HK$9.18; Kanglong Chemical (03759) fell 4.21% to HK$9.79.
Changes in Hong Kong stocks | Yao Ming Kangde (02359) once fell nearly 10%, leading a decline in CRO concept stocks last year's revenue exceeding 40 billion dollars, and growth still depended on the European and American markets
CRO concept stocks had the highest decline. As of press release, Pharmacovich (02359) fell 7.6% to HK$39.5; Kingsley Biotech (01548) fell 5.73% to HK$15.78; and Kanglong Chemical (03759) fell 3.54% to HK$10.34.
Zhaoyan Pharmaceutical (06127.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 15, 丨 Zhaoyan New Pharmaceutical (06127.HK) announced that a board meeting will be held on March 28, 2024 (Thursday) to consider and approve the Group's annual results for the year ended 31 December 2023, consider the proposed payment of a final dividend (if any), and deal with other matters.
JOINN: DATE OF BOARD MEETING
Changes in Hong Kong stocks | CRO concept stocks declined across the board, individual stocks led the decline, and BIO revised the press release saying that Pharmaceutical Kangde (02359) voluntarily terminated its BIO membership
The Zhitong Finance App learned that CRO concept stocks declined across the board, and individual Pharmaceutical stocks once again led the decline. As of press release, Pharmaceuticals (02359) fell 4.56% to HK$42.9; Zhaoyan New Pharmaceutical (06127) fell 4.37% to HK$10.06; Tiger Pharmaceuticals (03347) fell 1.63% to HK$33.1; Gloria Ying (06821) fell 0.97% to HK$71.1; furthermore, Pharmaceuticals (02268) fell 4.07% to HK$15.04. According to the news, on the evening of March 13, Bio announced that it would eliminate WuXi (Pharmaceutical Kangde)
Analysis
Price Target
No Data
